Insulin degludec/liraglutide in type 2 diabetes: a profile of its use

Heo, Young-A

doi:10.1007/s40267-020-00731-z

Drugs Ther Perspect

2020

DOI: 10.1007/s40267-020-00731-z

|View full text |Cite

Insulin degludec/liraglutide in type 2 diabetes: a profile of its use

Young-A Heo

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The background to this would be the spread of basal insulin and the clinical application of Zultophy as a combination of insulin and GLP-1Ra. It is Insulin Degludec/Liraglutide (IDegLira, Xultophy) which is a fixed-ratio combination (FRC) for convenient and useful clinical efficacy [20]. There were a series of Dual Action of Liraglutide and insulin degludec (DUAL) studies on Xultophy.…”

mentioning

confidence: 99%

Direction for Basal Insulin Therapy by Once Daily Injection in the Clinical Practice

Bando

2021

Diab Res Open Access

View full text Add to dashboard Cite

American Diabetes Association (ADA) has announced the new version of the standards of Medical Care in Diabetes-2021. The guideline of the diabetic patients with Older Adults seems to be used for a wide range of clinical practice. Among them, several impressive comments were found, where “Once-daily basal insulin injection therapy is associated with minimal side effects and maybe a reasonable option in many elder patients”. Recent topic includes Dual Action of Liraglutide and insulin degludec (DUAL) studies, and Xultophy has shown beneficial efficacy. Consequently, the trend would be developed from multiple daily injection (MDI) method to once daily injection.

show abstract

mentioning

confidence: 99%

Direction for Basal Insulin Therapy by Once Daily Injection in the Clinical Practice

Bando

2021

Diab Res Open Access

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Insulin degludec/liraglutide in type 2 diabetes: a profile of its use

Cited by 1 publication

References 48 publications

Direction for Basal Insulin Therapy by Once Daily Injection in the Clinical Practice

Direction for Basal Insulin Therapy by Once Daily Injection in the Clinical Practice

Contact Info

Product

Resources

About